Jay M. Phd Short Buys 29,082 Shares of BioAtla, Inc. (NASDAQ:BCAB) Stock

BioAtla, Inc. (NASDAQ:BCABGet Rating) CEO Jay M. Phd Short acquired 29,082 shares of the stock in a transaction that occurred on Tuesday, June 21st. The stock was purchased at an average price of $2.79 per share, with a total value of $81,138.78. Following the completion of the transaction, the chief executive officer now owns 1,335,674 shares of the company’s stock, valued at $3,726,530.46. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

BCAB traded up $0.06 during midday trading on Thursday, reaching $3.00. 334,368 shares of the company were exchanged, compared to its average volume of 650,754. BioAtla, Inc. has a one year low of $2.01 and a one year high of $47.86. The stock has a market capitalization of $112.24 million, a P/E ratio of -1.02 and a beta of 2.49. The stock’s 50-day simple moving average is $2.88 and its 200 day simple moving average is $7.95.

BioAtla (NASDAQ:BCABGet Rating) last issued its earnings results on Thursday, May 5th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.04. Equities analysts expect that BioAtla, Inc. will post -2.72 EPS for the current year.

Several large investors have recently added to or reduced their stakes in BCAB. Goldman Sachs Group Inc. lifted its holdings in shares of BioAtla by 308.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 46,709 shares of the company’s stock valued at $1,375,000 after purchasing an additional 35,270 shares in the last quarter. Credit Suisse AG lifted its holdings in shares of BioAtla by 129.7% during the 3rd quarter. Credit Suisse AG now owns 13,022 shares of the company’s stock valued at $384,000 after purchasing an additional 7,354 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of BioAtla by 19.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 8,337 shares of the company’s stock valued at $245,000 after purchasing an additional 1,350 shares in the last quarter. Tudor Investment Corp Et Al bought a new position in shares of BioAtla during the 3rd quarter valued at about $230,000. Finally, California State Teachers Retirement System lifted its holdings in shares of BioAtla by 43.8% during the 3rd quarter. California State Teachers Retirement System now owns 24,183 shares of the company’s stock valued at $712,000 after purchasing an additional 7,369 shares in the last quarter. Institutional investors and hedge funds own 70.79% of the company’s stock.

BCAB has been the subject of a number of research reports. HC Wainwright initiated coverage on BioAtla in a research report on Monday, March 21st. They issued a “buy” rating and a $25.00 price objective for the company. Credit Suisse Group cut BioAtla from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $5.00 in a report on Thursday, May 5th.

About BioAtla (Get Rating)

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.

Further Reading

Insider Buying and Selling by Quarter for BioAtla (NASDAQ:BCAB)

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.